Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Resverlogix Corp > Interference
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(33)
•••
Comment by toinv261on Jan 15, 2022 1:56pm
196 Views
Post# 34320509

RE:RE:RE:Interference

RE:RE:RE:InterferenceIt is incredibly pitiful. As 10-41 just posted on Agora other biotechs are making inroads on Covid.

I'm beginning to wonder if, because of Don's remarkable incompetence, RVX will ever achieve anything on any indication. The world is competitive and Covid has shown us the remarkable ability of thousands of bright biotech minds to innovate successfully.

Don is old, uneducated and not respected by the investment community and the biotech community.

Either Don will luck out on a Covid success or ORI will take him out. Signs don't look good on the Covid front based on current information from RVX.

It seems completely amazing that a biotech with such promising science can be managed with such incompetence.

Oh well, it is what it is...very sad indeed.

GLTA
Toinv
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities